NURS6521: Advanced Pharmacology Final Exam Q&A Actual
Exam 2026/2027 – Complete Exam-Style Questions with
Detailed Rationales | 100% Verified | Pass Guaranteed – A+
Graded
SECTION 1: Pharmacokinetics, Pharmacodynamics, & Pharmacogenomics (Q1-Q12)
Q1: A 68-year-old patient with atrial fibrillation is prescribed warfarin. The nurse
practitioner knows that warfarin has a narrow therapeutic index. Which laboratory
parameter is most critical to monitor to prevent bleeding or thrombosis?
A. Hemoglobin A1c
B. International normalized ratio (INR), target 2.0-3.0 for most indications [CORRECT]
C. Thyroid stimulating hormone
D. Prostate-specific antigen
Correct Answer: B
Rationale: Warfarin has a narrow therapeutic index with target INR of 2.0-3.0 for most
indications (2.5-3.5 for mechanical valves); subtherapeutic INR increases thrombosis
risk, while supratherapeutic INR increases bleeding risk, making frequent INR
monitoring essential for safe anticoagulation management. [100% VERIFIED – Walden
NURS6521 FINAL]
Q2: A patient taking tamoxifen for breast cancer is found to be a CYP2D6 poor
metabolizer. The nurse practitioner understands this pharmacogenomic finding means:
A. Tamoxifen will be more effective due to increased active metabolite formation
B. Tamoxifen will have reduced efficacy due to inadequate conversion to endoxifen
[CORRECT]
C. There is no clinical significance to CYP2D6 status with tamoxifen
D. The patient should increase the tamoxifen dose to overcome poor metabolism
Correct Answer: B
Rationale: Tamoxifen is a prodrug requiring CYP2D6-mediated conversion to endoxifen
(the active metabolite); poor metabolizers have significantly reduced endoxifen levels,
potentially compromising antiestrogenic efficacy and increasing breast cancer
,recurrence risk, suggesting consideration of alternative endocrine therapy. [100%
VERIFIED – Walden NURS6521 FINAL]
Q3: A patient on phenytoin for seizures is started on fluconazole for a fungal infection.
The nurse practitioner anticipates which change in phenytoin levels?
A. Decreased phenytoin levels due to enzyme induction
B. Increased phenytoin levels and toxicity risk due to CYP2C9/CYP2C19 inhibition
[CORRECT]
C. No interaction between these medications
D. Decreased phenytoin absorption
Correct Answer: B
Rationale: Fluconazole inhibits CYP2C9 and CYP2C19, which are primary enzymes
metabolizing phenytoin; this interaction increases phenytoin levels and toxicity risk
(nystagmus, ataxia, confusion), requiring phenytoin dose reduction and therapeutic drug
monitoring when fluconazole is initiated. [100% VERIFIED – Walden NURS6521 FINAL]
Q4: A patient with chronic pain is prescribed codeine. The nurse practitioner should
obtain which pharmacogenomic test to predict analgesic efficacy?
A. CYP3A4 genotyping
B. CYP2D6 genotyping [CORRECT]
C. CYP1A2 genotyping
D. HLA-B*5701 testing
Correct Answer: B
Rationale: Codeine is a prodrug requiring CYP2D6-mediated O-demethylation to
morphine for analgesic effect; poor metabolizers experience inadequate pain relief,
while ultra-rapid metabolizers (particularly common in Ethiopian and Saudi Arabian
populations) are at risk of morphine toxicity and respiratory depression. [100% VERIFIED
– Walden NURS6521 FINAL]
Q5: A patient on simvastatin begins drinking grapefruit juice daily. The nurse practitioner
counsels the patient that this combination increases risk of:
A. Hypoglycemia
B. Myopathy and rhabdomyolysis due to CYP3A4 inhibition [CORRECT]
C. Hypertensive crisis
D. Nephrogenic diabetes insipidus
,Correct Answer: B
Rationale: Grapefruit juice inhibits intestinal CYP3A4, increasing simvastatin
bioavailability and systemic exposure; this significantly increases myopathy and
rhabdomyolysis risk, particularly with higher simvastatin doses (80 mg contraindicated
with grapefruit), and patients should avoid grapefruit or switch to
pravastatin/fluxastatin. [100% VERIFIED – Walden NURS6521 FINAL]
Q6: A patient receives a loading dose of digoxin for atrial fibrillation with rapid
ventricular response. The purpose of the loading dose is to:
A. Reduce the drug's half-life
B. Achieve therapeutic plasma concentration rapidly [CORRECT]
C. Decrease the volume of distribution
D. Eliminate the need for maintenance dosing
Correct Answer: B
Rationale: Loading doses rapidly achieve therapeutic plasma concentrations in
situations requiring immediate effect (atrial fibrillation with RVR, heart failure);
maintenance doses then sustain steady-state levels (achieved after 4-5 half-lives,
approximately 7-10 days for digoxin) without the delay of titration from subtherapeutic
levels. [100% VERIFIED – Walden NURS6521 FINAL]
Q7: A patient with Asian ancestry is prescribed carbamazepine for trigeminal neuralgia.
Which pharmacogenomic testing should be obtained before initiation?
A. CYP2D6 genotyping
B. HLA-B1502 testing [CORRECT]
C. G6PD deficiency testing
D. CYP2C19 genotyping
Correct Answer: B
Rationale: HLA-B1502 allele is strongly associated with Stevens-Johnson syndrome and
toxic epidermal necrolysis in Asian populations treated with carbamazepine; FDA
recommends testing in patients of Han Chinese, Thai, Indian, and Filipino ancestry
before initiating carbamazepine or oxcarbazepine therapy. [100% VERIFIED – Walden
NURS6521 FINAL]
, Q8: A patient with G6PD deficiency is prescribed dapsone for Pneumocystis jirovecii
prophylaxis. The nurse practitioner recognizes this places the patient at risk for:
A. Nephrogenic diabetes insipidus
B. Hemolytic anemia due to oxidative stress on red blood cells [CORRECT]
C. Hyperthyroidism
D. Agranulocytosis
Correct Answer: B
Rationale: G6PD deficiency impairs the hexose monophosphate shunt, reducing NADPH
and glutathione production; oxidative stress from dapsone (and sulfonamides,
primaquine, nitrofurantoin) triggers hemolytic anemia in these patients, requiring G6PD
screening before initiating therapy. [100% VERIFIED – Walden NURS6521 FINAL]
Q9: A drug with low potency but high efficacy is best described as:
A. Requiring high doses to produce a maximal response [CORRECT]
B. Producing a strong effect at very low doses
C. Having a narrow therapeutic index
D. Being a competitive antagonist at the receptor
Correct Answer: A
Rationale: Potency refers to the dose required to produce a given effect (high potency =
low dose needed), while efficacy refers to the maximal response achievable; a drug can
have low potency (requires higher doses) but high efficacy (achieves full maximal
response), such as morphine compared to fentanyl. [100% VERIFIED – Walden
NURS6521 FINAL]
Q10: A patient on clopidogrel for coronary stent placement is found to be a CYP2C19
poor metabolizer. The nurse practitioner should consider which alternative antiplatelet?
A. Increasing the clopidogrel dose to 150 mg daily
B. Switching to prasugrel or ticagrelor [CORRECT]
C. Adding aspirin 81 mg daily only
D. Discontinuing all antiplatelet therapy
Correct Answer: B
Rationale: CYP2C19 poor metabolizers have reduced conversion of clopidogrel to its
active metabolite, increasing stent thrombosis and cardiovascular event risk; prasugrel
and ticagrelor are direct-acting P2Y12 inhibitors not dependent on CYP2C19
Exam 2026/2027 – Complete Exam-Style Questions with
Detailed Rationales | 100% Verified | Pass Guaranteed – A+
Graded
SECTION 1: Pharmacokinetics, Pharmacodynamics, & Pharmacogenomics (Q1-Q12)
Q1: A 68-year-old patient with atrial fibrillation is prescribed warfarin. The nurse
practitioner knows that warfarin has a narrow therapeutic index. Which laboratory
parameter is most critical to monitor to prevent bleeding or thrombosis?
A. Hemoglobin A1c
B. International normalized ratio (INR), target 2.0-3.0 for most indications [CORRECT]
C. Thyroid stimulating hormone
D. Prostate-specific antigen
Correct Answer: B
Rationale: Warfarin has a narrow therapeutic index with target INR of 2.0-3.0 for most
indications (2.5-3.5 for mechanical valves); subtherapeutic INR increases thrombosis
risk, while supratherapeutic INR increases bleeding risk, making frequent INR
monitoring essential for safe anticoagulation management. [100% VERIFIED – Walden
NURS6521 FINAL]
Q2: A patient taking tamoxifen for breast cancer is found to be a CYP2D6 poor
metabolizer. The nurse practitioner understands this pharmacogenomic finding means:
A. Tamoxifen will be more effective due to increased active metabolite formation
B. Tamoxifen will have reduced efficacy due to inadequate conversion to endoxifen
[CORRECT]
C. There is no clinical significance to CYP2D6 status with tamoxifen
D. The patient should increase the tamoxifen dose to overcome poor metabolism
Correct Answer: B
Rationale: Tamoxifen is a prodrug requiring CYP2D6-mediated conversion to endoxifen
(the active metabolite); poor metabolizers have significantly reduced endoxifen levels,
potentially compromising antiestrogenic efficacy and increasing breast cancer
,recurrence risk, suggesting consideration of alternative endocrine therapy. [100%
VERIFIED – Walden NURS6521 FINAL]
Q3: A patient on phenytoin for seizures is started on fluconazole for a fungal infection.
The nurse practitioner anticipates which change in phenytoin levels?
A. Decreased phenytoin levels due to enzyme induction
B. Increased phenytoin levels and toxicity risk due to CYP2C9/CYP2C19 inhibition
[CORRECT]
C. No interaction between these medications
D. Decreased phenytoin absorption
Correct Answer: B
Rationale: Fluconazole inhibits CYP2C9 and CYP2C19, which are primary enzymes
metabolizing phenytoin; this interaction increases phenytoin levels and toxicity risk
(nystagmus, ataxia, confusion), requiring phenytoin dose reduction and therapeutic drug
monitoring when fluconazole is initiated. [100% VERIFIED – Walden NURS6521 FINAL]
Q4: A patient with chronic pain is prescribed codeine. The nurse practitioner should
obtain which pharmacogenomic test to predict analgesic efficacy?
A. CYP3A4 genotyping
B. CYP2D6 genotyping [CORRECT]
C. CYP1A2 genotyping
D. HLA-B*5701 testing
Correct Answer: B
Rationale: Codeine is a prodrug requiring CYP2D6-mediated O-demethylation to
morphine for analgesic effect; poor metabolizers experience inadequate pain relief,
while ultra-rapid metabolizers (particularly common in Ethiopian and Saudi Arabian
populations) are at risk of morphine toxicity and respiratory depression. [100% VERIFIED
– Walden NURS6521 FINAL]
Q5: A patient on simvastatin begins drinking grapefruit juice daily. The nurse practitioner
counsels the patient that this combination increases risk of:
A. Hypoglycemia
B. Myopathy and rhabdomyolysis due to CYP3A4 inhibition [CORRECT]
C. Hypertensive crisis
D. Nephrogenic diabetes insipidus
,Correct Answer: B
Rationale: Grapefruit juice inhibits intestinal CYP3A4, increasing simvastatin
bioavailability and systemic exposure; this significantly increases myopathy and
rhabdomyolysis risk, particularly with higher simvastatin doses (80 mg contraindicated
with grapefruit), and patients should avoid grapefruit or switch to
pravastatin/fluxastatin. [100% VERIFIED – Walden NURS6521 FINAL]
Q6: A patient receives a loading dose of digoxin for atrial fibrillation with rapid
ventricular response. The purpose of the loading dose is to:
A. Reduce the drug's half-life
B. Achieve therapeutic plasma concentration rapidly [CORRECT]
C. Decrease the volume of distribution
D. Eliminate the need for maintenance dosing
Correct Answer: B
Rationale: Loading doses rapidly achieve therapeutic plasma concentrations in
situations requiring immediate effect (atrial fibrillation with RVR, heart failure);
maintenance doses then sustain steady-state levels (achieved after 4-5 half-lives,
approximately 7-10 days for digoxin) without the delay of titration from subtherapeutic
levels. [100% VERIFIED – Walden NURS6521 FINAL]
Q7: A patient with Asian ancestry is prescribed carbamazepine for trigeminal neuralgia.
Which pharmacogenomic testing should be obtained before initiation?
A. CYP2D6 genotyping
B. HLA-B1502 testing [CORRECT]
C. G6PD deficiency testing
D. CYP2C19 genotyping
Correct Answer: B
Rationale: HLA-B1502 allele is strongly associated with Stevens-Johnson syndrome and
toxic epidermal necrolysis in Asian populations treated with carbamazepine; FDA
recommends testing in patients of Han Chinese, Thai, Indian, and Filipino ancestry
before initiating carbamazepine or oxcarbazepine therapy. [100% VERIFIED – Walden
NURS6521 FINAL]
, Q8: A patient with G6PD deficiency is prescribed dapsone for Pneumocystis jirovecii
prophylaxis. The nurse practitioner recognizes this places the patient at risk for:
A. Nephrogenic diabetes insipidus
B. Hemolytic anemia due to oxidative stress on red blood cells [CORRECT]
C. Hyperthyroidism
D. Agranulocytosis
Correct Answer: B
Rationale: G6PD deficiency impairs the hexose monophosphate shunt, reducing NADPH
and glutathione production; oxidative stress from dapsone (and sulfonamides,
primaquine, nitrofurantoin) triggers hemolytic anemia in these patients, requiring G6PD
screening before initiating therapy. [100% VERIFIED – Walden NURS6521 FINAL]
Q9: A drug with low potency but high efficacy is best described as:
A. Requiring high doses to produce a maximal response [CORRECT]
B. Producing a strong effect at very low doses
C. Having a narrow therapeutic index
D. Being a competitive antagonist at the receptor
Correct Answer: A
Rationale: Potency refers to the dose required to produce a given effect (high potency =
low dose needed), while efficacy refers to the maximal response achievable; a drug can
have low potency (requires higher doses) but high efficacy (achieves full maximal
response), such as morphine compared to fentanyl. [100% VERIFIED – Walden
NURS6521 FINAL]
Q10: A patient on clopidogrel for coronary stent placement is found to be a CYP2C19
poor metabolizer. The nurse practitioner should consider which alternative antiplatelet?
A. Increasing the clopidogrel dose to 150 mg daily
B. Switching to prasugrel or ticagrelor [CORRECT]
C. Adding aspirin 81 mg daily only
D. Discontinuing all antiplatelet therapy
Correct Answer: B
Rationale: CYP2C19 poor metabolizers have reduced conversion of clopidogrel to its
active metabolite, increasing stent thrombosis and cardiovascular event risk; prasugrel
and ticagrelor are direct-acting P2Y12 inhibitors not dependent on CYP2C19
